US weighs next steps for J&J virus shot amid clot mystery

WASHINGTON DC: U.S. health officials are weighing next steps as they investigate a handful of unusual blood clots in people who received Johnson&Johnson's COVID19 vaccine a one-dose shot that many countries were eagerly awaiting to help speed virus protection.

It's not clear if the exceedingly rare reports so far, six cases out of more than 7 million inoculations in the U.S. really are linked to the J&J vaccine.

But the government recommended a pause in J&J vaccinations on Tuesday, just a week after European regulators declared that such clots are a rare but possible risk with the AstraZeneca vaccine, a shot made in a similar way but not yet approved for use in the U.S.

The clots occurred in strange places, in veins that drain blood from the brain, and in people with abnormally low levels of clot-forming platelets.

The six cases raised an alarm bell because that number is at least three times more than experts would have expected to see even of more typical braindrainage clots, said Dr. Tom Shimabukuro of the Centers for Disease Control and Prevention.

The CDC called its advisers together Wednesday for a public debate about how to handle the J&J vaccine while authorities nail down exactly what's happening.

What we have here is a picture of clots forming in large vessels where we have low platelets, Shimabukuro explained.

This usually doesn't happen, but it's similar to European reports with the AstraZeneca vaccine.

The clot concerns could undermine public confidence in a vaccine many hoped would help some of the hardest-toreach populations in poor countries or in places like homeless shelters in the U.S.

We know we are fighting a war against COVID-19, Dr. Peter Marks, the Food and Drug Administration's vaccine chief, said Tuesday. But when it comes to side effects, we don't, in the United States, have a lot of tolerance for friendly fire.

Health officials recommended the J&J timeout in part to make sure doctors know how to recognize and treat the unusual condition.

On Wednesday, the CDC said four of the six women with the unusual clots were treated with a blood thinner named heparin a treatment the government is warning doctors to avoid.

The U.S. set up intensive systems to track the safety of COVID-19 vaccines, knowing that side effects too rare to have occurred in studies of thousands of people could pop up once millions rolled up their sleeves. himabukuro said spotting such a rare potential risk amid the nation's huge vaccine rollout is an example of a success story for vaccine safety.